Prot #FOR46-001: A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Project: Research project

Project Details

StatusActive
Effective start/end date4/26/194/26/22

Funding

  • ICON Clinical Research, LLC (Prot #FOR46-001)
  • Fortis Therapeutics, Inc. (Prot #FOR46-001)